Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)
Phase 3
- Conditions
- psoriasis
- Registration Number
- JPRN-jRCT2080221614
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
Exclusion Criteria
-Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).
-Current drug-induced psoriasis.
-Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PASI 75
- Secondary Outcome Measures
Name Time Method PASI 50/75/90/100, IGA
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Secukinumab IL-17A inhibition mechanism Th17 pathway cytokine signaling chronic plaque psoriasis
Comparative effectiveness Secukinumab vs TNF inhibitors ustekinumab moderate severe plaque psoriasis
Biomarkers predicting response IL-17A inhibitors Secukinumab psoriasis patient selection pharmacogenomics
Secukinumab long-term safety adverse events infections Candida risk management plaque psoriasis
IL-17 inhibitors ixekizumab brodalumab bimekizumab comparison Secukinumab psoriasis therapeutic landscape